

FOR IMMEDIATE RELEASE

QT Vascular Announces Key Patent Granted in Singapore

- Glider™ product range expected to add to QT Vascular's regional growth in 2015
- Group continues to hit milestones and internal targets

Singapore, 10 December 2014 – Catalyst-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"), a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Singapore patent office has granted TriReme Medical LLC, its wholly owned US subsidiary, Singapore patent number 184930 for a "balloon catheter with improved column strength and torque". This technology is used in the Group's GliderXtreme™ PTA balloon catheter.

GliderXtreme™ PTA is part of TriReme Medical's Glider family of PTA and PTCA products which incorporate the combined features of a torque-able shaft and a skived tip. GliderXtreme™ PTA has an additional unique design feature, called "slide-lock", which provides for a low profile ($\leq 4F$) shaft with double the column strength compared to a conventional PTA balloon catheter. As such, GliderXtreme™ PTA provides exceptional pushability and crossability for treating long, tight and diffuse peripheral lesions.

GliderXtreme™ PTA balloon catheter already has regulatory clearance in Japan and China. Along with the Glider™ PTCA balloon catheter, sales of GliderXtreme™ PTA in Asia are expected to add to company growth in the region in 2015.

Dr. Eitan Konstantino, the Group's Chief Executive Officer commented: "This is another notch in the belt for the Group, as we continue to achieve key milestones and deliver on our internal targets. Singapore is the home base of the Group and we are delighted to obtain this patent here.

We are committed to driving value for our shareholders through innovative solutions that improve patients' lives and drive down healthcare costs. This patent, together with previously granted patents in Japan and China, is another step in building global value."

– End –

About Peripheral Arterial Disease

Peripheral artery disease (PAD) is caused by the build-up of fatty substances that collect and adhere to the linings of the arteries, in a process known as atherosclerosis. The build-up causes the internal lining of the artery to thicken, narrowing the artery and limiting blood flow to vital tissues and organs. Commonly affected arteries include those located in the legs, arms, neck and kidneys. The vast majority of patients with PAD also have significant concomitant coronary artery disease (CAD) and a high proportion of morbidity and mortality in these patients is related to myocardial infarction, ischemic stroke or cardiovascular death. PAD is estimated to affect 202 million people worldwide ⁽¹⁾.

About Coronary Artery Disease

Coronary artery disease occurs when the coronary arteries (the arteries surrounding the heart) become narrowed by a buildup of plaque, including cholesterol, fatty deposits, calcium, and other substances. As plaque accumulates over time, the diameter of the arterial lumen, or inner channel, narrows, resulting in reduced or stopped blood flow. When this occurs in arteries supplying blood to the heart, it can cause chest pain, a heart attack, or even death.

About QT Vascular Ltd.

QT Vascular Ltd. (QT Vascular) is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes. QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, in Pleasanton, California. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited on 29 April 2014.

For more information, please refer to: <http://www.qtvascular.com/>

⁽¹⁾ "Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis." 19 Oct 2013. The Lancet.

**Issued for and on behalf of QT Vascular Ltd.
by Financial PR Pte Ltd**


Kamal SAMUEL, kamal@financialpr.com.sg
Mark LIN, marklin@financialpr.com.sg
Tel: (65) 6438 2990 Fax: (65) 6438 0064

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

The Company was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the relevant rules of the SGX-ST. The Sponsor has not independently verified the contents of this press release.



80 Robinson Road #02-00 Singapore 068898

Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Mark Liew, Managing Director, Corporate Finance, at 20 Cecil Street, #21-02 Equity Plaza, Singapore 049705, telephone +65 6229 8088.